Menu
Washingtoner
  • Home
  • Financial
  • Home
  • Construction
  • Business
  • Technology
  • Crypto
  • Information Technology
  • Marketing
Washingtoner

Seagen Statement on Outcome of Daiichi Sankyo Arbitration
Washingtoner/10182820

Trending...
  • Tacoma: Homicide Investigation – 3500 block of E Grandview Ave
  • Tacoma: Community Events on January 12 and January 15 Offer Opportunities to Meet Interim Police Chief Patti Jackson
  • ANTOANETTA Partners With Zestacor Digital Marketing to Expand Online Presence for Handcrafted Luxury Jewelry
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today issued a statement regarding the outcome of the arbitration with Daiichi Sankyo Co. Ltd. ("Daiichi Sankyo") relating to the parties' 2008 collaboration agreement for the use of Seagen's antibody-drug conjugate (ADC) technology. The arbitrator ruled in favor of Daiichi Sankyo, citing statute of limitations and disagreement with Seagen on the interpretation of the contract.

"While we are disappointed with the arbitration decision, it was important for us to pursue this legal action," said Roger Dansey, M.D., interim Chief Executive Officer and Chief Medical Officer, Seagen. "This does not impact our existing business. Looking forward, we are well-positioned to drive continued innovation and growth with four commercial products and a deep and diverse pipeline of promising programs. Seagen remains focused on developing innovative medicines that make a meaningful difference in the lives of cancer patients."

More on Washingtoner
  • Waarom brand mentions in ChatGPT steeds belangrijker worden
  • Tacoma: City Council Approves 0.1% Criminal Justice Sales & Use Tax to Enhance Community Safety and Support Vital Services
  • Tacoma: District 5 Council Member Joe Bushnell to Serve as Deputy Mayor in 2026
  • City of Tacoma Secures Over $4 Million in Transportation Improvement Board Grants
  • Sandesh Sadalge Sworn in as District 4 Tacoma City Council Member for First Full Term

About Seagen

Seagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company's marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.

Forward Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to Seagen's continued innovation and growth, as well as its pipeline. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, the risk that the company's financial results may not be as expected and the difficulty and uncertainty of pharmaceutical product development. More information about the risks and uncertainties faced by the company is contained under the caption "Risk Factors" included in Seagen's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise except as required by applicable law.

More on Washingtoner
  • Tacoma: District 2 Council Member Sarah Rumbaugh Begins Second Term
  • Latasha Palmer Begins Serving as Tacoma City Council Member, At-Large Position 6
  • Mayor Anders Ibsen Sworn in During First Tacoma City Council Meeting of 2026
  • Yunishigawa Onsen's Annual "Kamakura Festival" will be held January 30 – March 1, 2026
  • At Your Service Plumbing Named a 2025 Nextdoor Neighborhood Fave

Contacts

For Media

David Caouette
(310) 430-3476
dcaouette@seagen.com

For Investors
Peggy Pinkston
(425) 527-4160
ppinkston@seagen.com
Show All News | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • Canyons & Chefs Announces Revamped Homepage
  • $140 to $145 Million in 2026 Projected and Profiled in New BD Deep Research Report on its Position in $57 Billion US Marine Industry; N Y S E: OTH
  • Really Cool Music Releases Its Fourth Single - "So Many Lost Years"
  • MGN Logistics Acquires Fast Service LLC, Fueling MyMGN Marketplace Expansion and Supercharging Expedited Coverage Nationwide
  • The Wait is Over: Salida Wine Festival Announces Triumphant 2026 Return After Seven-Year Hiatus
  • Graduates With $40K in Student Debt Are Buying Businesses Instead of Taking Entry-Level Jobs
  • Anne Seidman: Within the Lines
  • How Democrats Made Healthcare More Expensive in 2026
  • Inkdnylon Launches Bilingual Ask Inkdnylon Platform
  • JS Gallery Brings Global Voices to LA Art Show 2026 with "OFF SCRIPT" Exhibition
  • CareerWork$® Appoints Latoya Edmond as Executive Director
  • ANTOANETTA Partners With Zestacor Digital Marketing to Expand Online Presence for Handcrafted Luxury Jewelry
  • Lionshare Publishing LLC Announces January 2026 Release of The Unseen Swing
  • FrostSkin Launches Kickstarter Campaign for Patent-Pending Instant-Chill Water Purification Bottle
  • The New Monaco of the South (of Italy)
  • Tacoma: Homicide Investigation – 3500 block of E Grandview Ave
  • Lick Personal Oils Introduces the Ultimate Valentine's Day Gift Collection for Romantic, Thoughtful Gifting
  • Tacoma: Community Events on January 12 and January 15 Offer Opportunities to Meet Interim Police Chief Patti Jackson
  • Tacoma: Applicants Sought for the Commission on Immigrant and Refugee Affairs
  • GOOGL, META, or RDDT: which AI would choose? An in-depth, data-driven look at 2025–2026 dynamics
_catLbl0 _catLbl1

Popular on Washingtoner

  • City of Spokane Seeks Applicants for Park Board - 143
  • Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026 - 135
  • Spokane Police Department and SPD Cadets Engage with the Logan Community to Discuss Crime Prevention in the Neighborhood - 113
  • Spokane: Flags to be Lowered for Trooper Killed in Line of Duty
  • UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels
  • South Spokane Standoff Ends Peacefully After Suspect Surrenders to Officers
  • Tacoma City Council Passes Ordinance 29086 Amending the Rental Housing Code and Landlord Fairness Code Initiative
  • Spokane: Simple Police Contact for a Civil Bike Infraction Ends in Arrest After Suspect Flees from Officers; Stolen Property Recovered After Suspect is Taken into Custody
  • Terizza Forms Strategic Collaboration with UC San Diego to Pioneer Next-Generation Distributed AI Infrastructure
  • Tacoma: Homicide Investigation – 3500 block of E Grandview Ave

Similar on Washingtoner

  • Revenue Optics Appoints Ljupco Icevski as Executive Advisor in Strategic Move to Accelerate Commercial Development
  • Scoop Social Co. Partners with Air Canada to Celebrate New Direct Flights to Milan with Custom Italian Piaggio Ape Gelato Carts
  • Breakout Phase for Public Company: New Partnerships, Zero Debt, and $20 Million Growth Capital Position Company for 2026 Acceleration
  • Global License Exclusive Secured for Emesyl OTC Nausea Relief, Expanding Multi-Product Growth Strategy for Caring Brands, Inc. (N A S D A Q: CABR)
  • RNHA Affirms Support for President Trump as Nation Marks Historic Victory for Freedom
  • $140 to $145 Million in 2026 Projected and Profiled in New BD Deep Research Report on its Position in $57 Billion US Marine Industry; N Y S E: OTH
  • MGN Logistics Acquires Fast Service LLC, Fueling MyMGN Marketplace Expansion and Supercharging Expedited Coverage Nationwide
  • Graduates With $40K in Student Debt Are Buying Businesses Instead of Taking Entry-Level Jobs
  • How Democrats Made Healthcare More Expensive in 2026
  • Inkdnylon Launches Bilingual Ask Inkdnylon Platform
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute